Autopsy report · NCT06754761
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
Cause of deathFunding or business
“A decision, based solely on business strategy, was taken to terminate study D533BC00002 on 22 December 2025, as the clinical development programme for ceralasertib has been discontinued.”
Life of this trial
- Registered 11 months before it started.
- Ran for about 1 month before it stopped.
- 2 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Neoplasm
- Interventions
- [14C] AZD6738; AZD6738 / ceralasertib
- Participants
- 2
- Sites
- 1
- Countries
- United Kingdom
Trials that died the same way
- Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
“The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.” - A Study Of PF-06664178 In Patients With Advanced Solid Tumors
“The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.” - A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
“Study terminated due to various reasons impacting the feasibility of future clinical development” - A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis
“The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.” - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.